Astellas Pharma and Drais Pharmaceuticals have partnered to develop and commercialize a melanocortin receptor agonist for the potential treatment of ulcerative colitis through Telsar Pharma. Under the agreement, Astellas will transfer all ...
CeeTox and Cellular Dynamics International (CDI) have introduced a new predictive cardiac safety screening service, Cardiac Arrhythmia Assessment Screen (CAAS), which uses human induced pluripotent stem (iPS) cell-derived cardiomyocytes. ...
Towers Watson, a professional services company , effective from November 1, 2012, replacing Walter Bardenwerper, who is retiring at the end of November. Towers Watson chairman and CEO John Haley said Kirkland's proven track record during ...
Tags: Towers Watson, Kirkland L Hicks, general counse, insurance service
Selcia Limited has launched a new platform that enables drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (PPIases). The scope of the service includes drug screening, functional assays, compound ...
Tags: Selcia Limited, PPIases, drug screening, functional assays
The European Commission (EC) has granted a €6m grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501. The FIGHT HLH consortium lead by NovImmune ...
US Department of Defense has granted a Congressionally Directed Medical Research Programs (CDMRP) grant to Aduro BioTech to complete the preclinical development of a new therapeutic cancer vaccine for prostate cancer. Aduro's cancer ...
Tags: Aduro, cancer vaccine platform, IND
TG Therapeutics and Ildong Pharmaceutical have signed a licensing deal to develop and commercialize an oncology candidate, Ublituximab, in South Korea and Southeast Asia. Under the contract, Ildong gains Ublituximab development rights in ...
Tags: TG, Ildong Pharmaceutical, Ublituximab
Cara Therapeutics and Chong Kun Dang Pharmaceutical have signed licensing contract to develop and market CR845, an analgesic drug candidate, in the Republic of Korea. As a part of the agreement, Cara is eligible to gain an up-front ...
Tags: analgesic drug candidate, licensing contract, CR845, Cara Therapeutics
Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer. The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) ...
Tags: cancer therapeutics, CTx-294886, basal breast cancer, FAK inhibitor
Novavax has reported a net loss of $7.22m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss of $3.21m, or $0.03 per share, for the third quarter ended 30 September 2011. Revenue for third quarter of ...
Tags: Novavax, Wider Q3 Net Loss, net loss, clinical trials
Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased loss is due to the $155,000 increase in ...
Tags: Net Loss, therapeutic cancer vaccine, immune enhancement technology
Galapagos, a mid-size biotechnology company, has delivered the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. Servier and Galapagos entered into an alliance in July 2010 to develop new oral medicines ...
Tags: Galapagos Identifies Drug, Galapagos, Servier, osteoarthritis
Forest Laboratories and Adamas Pharmaceuticals have collaborated for the development of a fixed dosed combination (FDC) of Namenda XR and donepezil HCl for Alzheimer's dementia in the US. The company expects to launch the FDC that will be ...
Lectra, world leader in integrated technology solutions dedicated to industries using soft materials—textiles, leather, industrial fabrics, and composite materials—is pleased to announce the appointment of Maurizio Sapio as ...
Tags: Italy, Lectra, Maurizio Sapi, Sales Director
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system. The patent application No.13/032,029 covers claims for ...
Tags: siRNA delivery system, US Patent, dynamic polyconjugate, DPC platform